12,200 Shares in Janux Therapeutics, Inc. (NASDAQ:JANX) Acquired by Teachers Retirement System of The State of Kentucky

Teachers Retirement System of The State of Kentucky acquired a new position in shares of Janux Therapeutics, Inc. (NASDAQ:JANX) in the fourth quarter, according to its most recent filing with the Securities and Exchange Commission. The institutional investor acquired 12,200 shares of the company’s stock, valued at approximately $653,000.

Other institutional investors have also added to or reduced their stakes in the company. Russell Investments Group Ltd. grew its holdings in Janux Therapeutics by 77.7% during the 4th quarter. Russell Investments Group Ltd. now owns 1,011 shares of the company’s stock worth $54,000 after acquiring an additional 442 shares during the last quarter. Avanza Fonder AB bought a new stake in Janux Therapeutics during the 4th quarter worth approximately $139,000. Meeder Asset Management Inc. bought a new stake in Janux Therapeutics during the 4th quarter worth approximately $159,000. Chicago Capital LLC bought a new stake in Janux Therapeutics during the 4th quarter worth approximately $230,000. Finally, Cerity Partners LLC bought a new stake in Janux Therapeutics during the 4th quarter worth approximately $239,000. 75.39% of the stock is currently owned by institutional investors and hedge funds.

Analysts Set New Price Targets

A number of equities research analysts have recently commented on the stock. William Blair reaffirmed an “outperform” rating on shares of Janux Therapeutics in a research note on Friday, January 10th. Wedbush reaffirmed an “outperform” rating and issued a $76.00 price objective (up from $75.00) on shares of Janux Therapeutics in a research note on Friday, February 28th. HC Wainwright reaffirmed a “buy” rating and issued a $70.00 price objective on shares of Janux Therapeutics in a research note on Monday, March 3rd. Finally, Scotiabank dropped their price objective on shares of Janux Therapeutics from $62.00 to $41.00 and set a “sector perform” rating on the stock in a report on Friday, February 28th. One research analyst has rated the stock with a hold rating, eight have assigned a buy rating and two have issued a strong buy rating to the company’s stock. According to MarketBeat, Janux Therapeutics has a consensus rating of “Buy” and a consensus price target of $95.25.

Insider Activity

In other news, Director Ra Capital Management, L.P. purchased 110,206 shares of the stock in a transaction on Friday, March 7th. The shares were acquired at an average price of $31.02 per share, for a total transaction of $3,418,590.12. Following the completion of the transaction, the director now directly owns 10,141,287 shares of the company’s stock, valued at approximately $314,582,722.74. This trade represents a 1.10 % increase in their position. The acquisition was disclosed in a filing with the SEC, which is available through this link. Also, insider Andrew Hollman Meyer sold 3,334 shares of the company’s stock in a transaction dated Monday, February 3rd. The stock was sold at an average price of $42.29, for a total value of $140,994.86. Following the completion of the transaction, the insider now owns 82,139 shares of the company’s stock, valued at $3,473,658.31. The trade was a 3.90 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold a total of 10,002 shares of company stock valued at $348,203 over the last three months. Corporate insiders own 29.40% of the company’s stock.

Janux Therapeutics Stock Performance

Shares of JANX opened at $32.23 on Tuesday. The stock has a 50 day moving average price of $29.97 and a two-hundred day moving average price of $42.96. The firm has a market capitalization of $1.90 billion, a P/E ratio of -27.55 and a beta of 3.27. Janux Therapeutics, Inc. has a 52 week low of $22.52 and a 52 week high of $71.71.

Janux Therapeutics (NASDAQ:JANX) last released its earnings results on Thursday, February 27th. The company reported ($0.36) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.49) by $0.13. Janux Therapeutics had a negative return on equity of 10.47% and a negative net margin of 463.91%. On average, equities analysts forecast that Janux Therapeutics, Inc. will post -1.38 earnings per share for the current year.

Janux Therapeutics Profile

Janux Therapeutics, Inc, a clinical stage biopharmaceutical company, develops immunotherapies based on Tumor Activated T Cell Engagers (TRACTr) and Tumor Activated Immunomodulators (TRACIr) platforms technology to treat patients suffering from cancer. The company's clinical candidates comprise JANX007, a prostate-specific membrane antigen or PSMA-TRACTr, which is in Phase 1 clinical trial in adults for the treatment of metastatic castration-resistant prostate cancer (mCRPC) and the vasculature of other tumors; and JANX008, an epidermal growth factor receptor or EGFR-TRACTr that is in Phase 1 clinical trial for the treatment of multiple solid cancers, including colorectal cancer, squamous cell carcinoma of the head and neck, non-small cell lung cancer, and renal cell carcinoma.